Upgrade to SI Premium - Free Trial

Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold

June 1, 2026 6:37 PM
Stifel analyst James Condulis downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Buy to Hold with a price target of $3.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades